Caris Life Sciences Archives

TGen-TD2-Scottsdale Healthcare study benefits patients


The Side-Out Foundation’s breast cancer pilot study, led by the Translational Genomics Research Institute (TGen), Translational Drug Development (TD2) and Scottsdale Healthcare, has shown that cancer patients do better when their treatment is guided by molecular profiling. Specifically, 52 percent of patients with advanced breast cancer received clinical benefit – meaning their disease was controlled… Read More →